Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers November 20, 2017
Pharmacy Choice - Pharmaceutical News - British Biotech Receives 52M Boost To Beat Antimicrobial Resistance with New Antibiotic [Arab Times (Kuwait)] - November 20, 2017

Pharmacy News Article

 9/13/17 - British Biotech Receives 52M Boost To Beat Antimicrobial Resistance with New Antibiotic [Arab Times (Kuwait)]

Summit Therapeutics, a biopharma company operating in the UK and US, has received the Barda Contract, designed to counter public health emergencies. In this case, the money will help to fight antimicrobial resistance and hospital-acquired infections by supporting the clinical and regulatory development of ridinilazole, a new treatment for Clostridium difficile infections. Currently, C. difficile is responsible for 8% of all hospital-acquired infections, and almost 4,000 deaths in Europe annually.

Summit will initially receive $32B (26B) to fund regulatory approval for a Phase III study and begin patient enrollment. An extra $30B (25B) will become available if they meet performance-related targets, for example, 2 planned Phase III clinical trials and the submission of a marketing application in the US.

Ridinilazole is a highly selective small molecule antibiotic. Its narrow spectrum of activity is hugely beneficial as it leaves the helpful bacteria living in our guts unharmed. In a Phase II study, it outperformed vancomycin by substantially reducing rates of disease recurrence while preserving the microbiome. Its exact mechanism of action is not yet known. However, discovering how it specifically targets C. difficile and leaves the gut flora untouched would be very useful in this field.

The discovery of new antibiotics is not too enticing to big pharma due to the speed at which bacteria develop resistance meaning new products could have a limited lifetime. One alternative is a bacteriophage, a virus that infects and kills bacteria with high specificity. The University of Leicester, in collaboration with California-based biotech AmphliPhi, demonstrated the efficacy of these against C. difficile.

Although news of ridinilazole performing so well in clinical studies is great to hear, we cannot ignore the reason we are so desperately looking for new antibiotics. Despite the efforts of companies such as Basilea, AiCuris, and Curetis, resistance to antibiotics is growing at a rate that we cannot keep up with, and resistant infections kill around 700,000 people each year.

But, Summit is confident that it is onto a winner, with Glyn Edwards, CEO, saying: BARDAs selection of ridinilazole for an award is testament to ridinilazoles promising clinical and preclinical data package that indicate its potential as a front-line treatment of CDI that could reduce recurrent disease. Fingers crossed that is the case.

(c) 2017 Arab Times Kuwait English Daily. All Rights Reserved. Provided by SyndiGate Media Inc. (

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Last Chance
Nov 20: Obesity Management: Overview of Pharmacotherapy
Last Chance
Nov 21: Standards of Practice for Filling Controlled Substance Prescriptions in Florida
Nov 22: Medical Marijuana: Examining the Science, Not the Politics
Nov 27: Drug Diversion and the Law: Updates and Considerations
Nov 28: An Integrative Approach to Managing Arthritis
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.

Websites »
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement